Research

Participate in the Annual Cure SMA Community Update Survey – Open Now!

April 4, 2024
Posted in ,

For the past seven years, the Cure SMA Community Update Survey has collected data and information on the SMA community’s experiences and daily challenges. Every […]

Read More ›

Cure SMA Awards $150,000 Grant to Lyndsay Murray,PhD, at the University of Edinburgh in Scotland

April 3, 2024
Posted in , ,

Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in SMA […]

Read More ›

Cure SMA Awards $114,000 Grant to Michael Tellier, PhD, at the University of Leicester in the United Kingdom

March 21, 2024
Posted in , ,

Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in SMA […]

Read More ›

Apitegromab Linked to Improved Outcomes for Those with Spinal Muscular Atrophy

March 12, 2024
Posted in , ,

The study included 58 individuals with SMA types 2 and 3 who were treated with IV apitegromab for 52 weeks. At 36 months, treatment resulted […]

Read More ›

Cure SMA Awards $150,000 Grant to Allison Ebert, PhD, at The Medical College of Wisconsin

March 8, 2024
Posted in , ,

Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in SMA […]

Read More ›

Cure SMA Awards $100,000 Grant to Elana Molotsky, PhD, at the Johns Hopkins University School of Medicine

February 26, 2024
Posted in , ,

Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in SMA […]

Read More ›

Cure SMA Awards $150,000 Grant to Melissa Bowerman, PhD, at Keele University

February 21, 2024
Posted in , ,

Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in SMA […]

Read More ›

Analysis: Cure SMA’s Risk/Benefit Survey

December 20, 2023
Posted in , ,

One of Cure SMA’s top priorities is to relay the SMA community’s treatment experiences and preferences to the United States Food and Drug Administration (FDA). […]

Read More ›

Identifying Biomarkers of Spinal Muscular Atrophy for Further Development

September 28, 2023
Posted in ,

An important part of Cure SMA’s core mission is to carry out and support research that will improve the quality of life for all people […]

Read More ›

Biohaven Completes Enrollment in Pivotal Phase 3 Study

September 19, 2023
Posted in , , ,

Recently, Biohaven released a statement on the completed enrollment of their pivotal Phase 3 Study of Taldefgrobep Alfa in people with SMA. Check out Biohaven’s […]

Read More ›
Scroll to Top